A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI

Exclusion Criteria

• •1. Patients who have received one or more prior systemic anticancer treatment regimens for clear cell renal cell carcinoma;
• •2. Patients who have not previously received immunosuppressive therapy for advanced renal cell carcinoma;
• •3. Subjects currently undergoing anticancer therapy (excluding local radiotherapy for bone metastases);
• •4. Subjects with known hypersensitivity to similar drugs;
• •5. Subjects with active infectious diseases;
• •6. Any uncontrolled clinical condition;
• •7. Undergone major surgery within 4 weeks prior to enrollment;
• •8. History of significant psychiatric disorders that may impair understanding of informed consent or compliance with the study protocol;
• •9. Any condition affecting the subject's ability to swallow medication;
• •10. Pregnant or lactating women;
• •11. Subjects with severe pulmonary disease, asthma, or COPD history, with pulmonary function tests indicating moderate or greater impairment;
• •12. Any other factors deemed by the investigator to make the subject unsuitable for participation in the study.